TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
$CHAI-DISCOVERY · Chai Discovery's Bitter Lesson: Drug Design Is Another Scaling Problem
now playing · $CHAI-DISCOVERY
$CHAI-DISCOVERYbullish· high· posjosh
Chai Discovery aims to make drug discovery an engineering discipline via AI
Chai Discovery is building a computer-aided design suite for molecules to transform drug discovery from serendipitous screening to intentional engineering, using AI to create abst…
$CHAI-DISCOVERYbullish· high· posjosh
Chai Discovery founders articulate thesis: AI-driven molecular design suite to industrialize drug discovery
Chai Discovery is building a computational design suite for molecules that transforms drug discovery from trial-and-error to engineering, using diffusion models and scaling laws t…
$CHAI-DISCOVERYbullish· high· posmatt
Chai 2 achieves 15% antibody binding rate vs 0.1% prior art
Chai Discovery's Chai 2 model reaches 15% success rate in de novo antibody design versus 0.1% state-of-the-art, enabling zero-shot molecule generation with sufficient hits for sta…
$CHAI-DISCOVERYbullish· high· posmatt
Bitter lesson drives Chai: scaling laws beat hand-crafted modules
Chai Discovery follows the 'bitter lesson' — scaling compute, data, and simple architectures outperforms complex hand-engineered modules; identifying scaling laws lets models auto…
$CHAI-DISCOVERYbullish· high· posmatt
Platform model chosen over full-stack: pharma partnerships create rigor flywheel
Chai Discovery chose an infrastructure/platform model partnering with pharma giants (Eli Lilly, Novartis, Organon, Pfizer) over full-stack drug development; partnerships force mod…
$CHAI-DISCOVERYbullish· high· posjosh
Chai clears traditional methods bar: Andy Young's 20-year expertise validates models
Chai Discovery's models have cleared the adoption bar set by traditional wet-lab experts like Andy Young (20 years at Pfizer/Genentech, drug approval), proving AI can match or exc…
$CHAI-DISCOVERYbullish· high· posmatt
Deployment flywheel spinning: pharma partners using models on real disease programs
Chai Discovery's models are now deployed with pharma partners on real programs targeting devastating diseases; zero-shot molecules advancing to clinic within a year, with potentia…